https://www.washingtonpost.com/business/2020/05/26/remdesivir-coronavirus-taxpayers/
Gilead plans to invest $1B in 2020 for remdesivir manufacturing. Process to get approval as a treatment for COVID-19 costing tens of millions, but US taxpayers footing the bill for that.
Perhaps the opportunity before us with hinokitiol on top of everything else warrants a significant capital raise. $50m in a Nasdaq IPO for 10% of the company? This would also solve the stock's liquidity issue, imo.
Ann: Business Update, page-22
-
- There are more pages in this discussion • 152 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ANO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.71M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1999 | 78.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 90.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.12pm 27/09/2024 (20 minute delay) ? |
| ANO (ASX) Chart |
Day chart unavailable